Evidence map›Paper›PMID 40307389›Full record

ArticleScientific reports2025

FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury.

Yijie Cheng, Yuxin Yang, Yan Su, Ruihuan Chen, Da Qian, Jingyuan Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yijie ChengPharmacy Department, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, China.
Yuxin YangSchool of Biology and Food Engineering, Changshu Institute of Technology, Changshu, China.
Yan SuSchool of Biology and Food Engineering, Changshu Institute of Technology, Changshu, China.
Ruihuan ChenPharmacy Department, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, China.
Da QianCentral Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, China. drqianda@hotmail.com.
Jingyuan XuCentral Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, China. xujingyuanxu@126.com.

Funding

National Natural Science Foundation of China 82003885Suzhou science and technology plan project SNG2022027
6 · The paper itself

Abstract

Taxanes play a crucial role in cancer treatment, particularly for non-small cell lung cancer and breast cancer. However, real-world studies examining drug-induced liver injury (DILI) associated with these drugs remain limited. Our study investigates the association between taxanes and DILI through analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, alongside an exploration of potential hepatotoxicity mechanisms via network pharmacology. We collected DILI reports related to taxanes from the FAERS database between January 2004 and March 2024, employing disproportionality analyses with the reporting odds ratio (ROR) and 95% confidence intervals. Our findings revealed a significant association between paclitaxel (ROR = 2.35) and nab-paclitaxel (ROR = 3.14) with DILI, while docetaxel demonstrated no significant correlation (ROR = 0.68), although it was linked to higher mortality rates and earlier onset. Network pharmacology analysis uncovered that the mechanisms of liver injury induced by these two drugs may not be entirely congruent. Unique targets for docetaxel included BCL2, CNR2, and MAPK1, while the 'Regulation of lipolysis in adipocytes' pathway was specifically associated with docetaxel-induced DILI. Our findings indicate that taxanes exhibit differential hepatotoxic risks and hepatotoxicity mechanisms, emphasizing the need for enhanced drug safety monitoring strategies for cancer patients.

Indexed as

Adverse Drug Reaction Reporting SystemsAntineoplastic AgentsChemical and Drug Induced Liver InjuryNetwork PharmacologyTaxoidsAlbuminsDatabases, FactualDocetaxelFemaleHumansMalePaclitaxelUnited StatesUnited States Food and Drug Administration130-nm albumin-bound paclitaxelAlbuminsAntineoplastic AgentsDocetaxelPaclitaxelTaxoidsDisproportionality analysesDrug-Induced liver injuryFAERS databaseNetwork PharmacologyReporting odds ratioTaxanes

Identifiers

PMID40307389
PMCPMC12043806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.